News & Updates

Show Multimedia Only

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

A more selective risk-based approach to an enoxaparin thromboprophylaxis protocol appears to reduce the incidence of wound hematomas without increasing the rates of postpartum venous thromboembolism (VTE), as shown in a retrospective study.

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

Personalized faricimab dosing shows durable efficacy in nAMD

30 Jul 2024 by

A treat-and-extend personalized treatment with faricimab based on disease activity results in sustained gains in vision or anatomic outcomes through 2 years in patients with neovascular age-related macular degeneration (nAMD), reports a study. Moreover, nearly four in five (80 percent) patients have achieved extended dosing intervals of 12 weeks or more.

Personalized faricimab dosing shows durable efficacy in nAMD

30 Jul 2024

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

30 Jul 2024 by

The addition of dostarlimab to a carboplatin-paclitaxel (CP) chemotherapy regimen confers an overall survival (OS) benefit in women with primary advanced or recurrent endometrial cancer (EC), according to the second interim analysis of the ENGOT-EN6/GOG-3031/RUBY trial part 1.

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

30 Jul 2024

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

29 Jul 2024

The use of oral corticosteroids for more than 90 days among individuals with atopic dermatitis (AD) appears to be associated with a slight increase in the risk of adverse events (AEs), according to a study.

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

29 Jul 2024

Nalbuphine nasal spray on par with injectable solution in orthopaedic procedures

29 Jul 2024

The nalbuphine nasal spray Apain may be used as a safe and noninvasive alternative to intramuscular nalbuphine for the relief of severe pain in patients who underwent orthopaedic interventions and traumatological procedures, suggests a study.

Nalbuphine nasal spray on par with injectable solution in orthopaedic procedures

29 Jul 2024

Does race/ethnicity affect the safety, efficacy of semaglutide?

29 Jul 2024 by

A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.

Does race/ethnicity affect the safety, efficacy of semaglutide?

29 Jul 2024

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

28 Jul 2024

Individuals who received systemic fluoroquinolone do not appear to have an increased risk of uveitis or retinal detachment, as shown in a study.

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

28 Jul 2024

Is sugammadex better than neostigmine for preventing postoperative complications?

28 Jul 2024 by

Treatment with sugammadex for the reversal of neuromuscular blockade falls short of significantly reducing the risk of postoperative pulmonary complications (PPCs) when compared with neostigmine, as shown in a recent study.

Is sugammadex better than neostigmine for preventing postoperative complications?

28 Jul 2024

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

28 Jul 2024

Supplementation with the re-esterified triglyceride (rTG) form of omega-3 fatty acid does not help ameliorate the symptoms of dry eye disease (DED) associated with meibomian gland dysfunction, as shown in a study.

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

28 Jul 2024

Adults with schizophrenia get long-term benefits with paliperidone palmitate

27 Jul 2024 by

More than 90 percent of adult patients with schizophrenia who continued to receive the long-acting injectable (LAI) antipsychotic paliperidone palmitate for another 2 years after completing a 1-year treatment course remained relapse-free, with no new safety signals emerging, according to an open-label extension (OLE) study.

Adults with schizophrenia get long-term benefits with paliperidone palmitate

27 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

Personalized faricimab dosing shows durable efficacy in nAMD

Personalized faricimab dosing shows durable efficacy in nAMD

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

Nalbuphine nasal spray on par with injectable solution in orthopaedic procedures

Nalbuphine nasal spray on par with injectable solution in orthopaedic procedures

Does race/ethnicity affect the safety, efficacy of semaglutide?

Does race/ethnicity affect the safety, efficacy of semaglutide?

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

Systemic fluoroquinolone treatment not a risk factor for uveitis, retinal detachment

Is sugammadex better than neostigmine for preventing postoperative complications?

Is sugammadex better than neostigmine for preventing postoperative complications?

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

Re-esterified triglyceride omega-3 trial yields null results for dry eye disease

Adults with schizophrenia get long-term benefits with paliperidone palmitate

Adults with schizophrenia get long-term benefits with paliperidone palmitate